A randomised, double-blind, study comparing ARIMIDEX™ with NOLVADEX™ as neo-adjuvant and adjuvant treatment in postmenopausal women with large operable (T2 [≥3 cm], T3, N0-2, M0) or potentially-operable, locally advanced (T4b, N0-2, M0), ER+ and/ or PR+ breast cancer